An infection of hepatitis C virus may lead to serious liver diseases including chronic hepatitis, cirrhosis and hepatocellular carcinoma with poor prognosis [
1-
4]. HCV is an enveloped virus with a single-stranded positive-sense RNA genome of about 9.6

kb encoding 10 different proteins, including 3 structural proteins core, E1, E2 and 7 nonstructural proteins p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B [
5-
7].
Besides causing liver diseases, HCV may lead to some extra-hepatic complications including type 2 diabetes mellitus (T2DM) [
8] based on some epidemiological evidences. Furthermore, regardless of cirrhosis, the prevalence of T2DM of patients with HCV infection was much higher than that of patients with HBV infection [
9-
11]. It clearly indicated that HCV may somehow involve in the pathogenesis of T2DM, which causes hyperglycemia that involving multiple factors, especially insulin resistance [
12]. Individuals with insulin resistance may produce sufficient insulin, but can’t effectively reduce blood sugar level because of resisting the function of the insulin, which mainly involves an impairment of insulin signaling pathway. Insulin receptor (IR) is a receptor with tyrosine kinase located on plasma membrane which contains two subunits, α and β subunits [
13,
14]. The tyrosine residues of IRS-1 also can be phosphorylated to turn on the insulin signaling pathway. The phosphorylated IRS-1 actives phosphatidylinositol 3-kinase (PI3K) that promote Phosphatidylinositol 4, 5-bisphosphate (PIP
2) conversion into phosphatidylinositol-3,4,5-triphosphate (PIP
3) following leads to Akt/PKB (protein kinase B) undergoes serine/threonine phosphorylation at the residues of Ser473 and Thr308 [
15,
16]. Finally, it promotes glucose transporter-4 (GLUT-4) translocation to plasma membrane to enhance glucose uptake [
17,
18]. According to the mechanism of insulin resistance, impairment of activation of Akt/PKB or GSK3 is the key role which can inhibit glucose uptake or glycogen synthesis, respectively.
Evidences indicated that cells expressing HCV proteins possess impaired insulin signaling [
19]. Among HCV proteins, core protein was the most investigated target with extensive data accumulated during recent years [
20-
22]. Studies suggested that core protein might inhibit insulin signaling through increasing the expression of suppressors of cytokine signaling 3 (SOCS3) [
20] or upregulating serine phosphorylation of IRS-1 by activation of c-Jun N-terminal kinase (JNK) [
21]. The resultant event is the impairment of IRS-1 function and the downstream signaling. Such core protein-related mechanisms seem genotype-specific [
22]. However, the involvement of HCV proteins other than core protein have not been investigated. Among them, E2 is mainly responsible for viral entry and plays an important role for virus infection. Nevertheless, the involvement of E2 in type 2 DM has not been investigated. Some evidences suggested HCV E2 protein could activate extracellular signal-regulated kinase (ERK) signaling which interact with cell surface CD81 [
23-
25]. ERK is one of the IRS-1 kinases which can upregulate serine phosphorylation of IRS-1 following an inhibition of IRS-1 function and eventually leading to insulin resistance [
26]. Therefore, this study was conducted to understand the ability of HCV E2 for the induction of insulin resistance and the role of HCV E2 protein in insulin signaling pathway in hepatocytes.